- Home
- KEN vs TARS Comparison
KEN vs TARS Comparison
Compare KEN & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEN
- TARS
- Stock Information
- Founded
- KEN 2014
- TARS 2016
- Country
- KEN Singapore
- TARS United States
- Employees
- KEN N/A
- TARS N/A
- Industry
- KEN Electric Utilities: Central
- TARS Medicinal Chemicals and Botanical Products
- Sector
- KEN Utilities
- TARS Health Care
- Exchange
- KEN Nasdaq
- TARS Nasdaq
- Market Cap
- KEN 2.7B
- TARS 2.8B
- IPO Year
- KEN N/A
- TARS 2020
- Fundamental
- Price
- KEN $56.90
- TARS $74.39
- Analyst Decision
- KEN
- TARS Strong Buy
- Analyst Count
- KEN 0
- TARS 7
- Target Price
- KEN N/A
- TARS $69.86
- AVG Volume (30 Days)
- KEN 8.7K
- TARS 494.1K
- Earning Date
- KEN 12-04-2025
- TARS 11-04-2025
- Dividend Yield
- KEN 8.49%
- TARS N/A
- EPS Growth
- KEN N/A
- TARS N/A
- EPS
- KEN 9.36
- TARS N/A
- Revenue
- KEN $774,304,000.00
- TARS $366,100,000.00
- Revenue This Year
- KEN N/A
- TARS $139.46
- Revenue Next Year
- KEN N/A
- TARS $49.91
- P/E Ratio
- KEN $6.10
- TARS N/A
- Revenue Growth
- KEN 5.38
- TARS 182.44
- 52 Week Low
- KEN $27.10
- TARS $38.51
- 52 Week High
- KEN $58.32
- TARS $76.81
- Technical
- Relative Strength Index (RSI)
- KEN 74.70
- TARS 61.52
- Support Level
- KEN $51.84
- TARS $70.84
- Resistance Level
- KEN $58.32
- TARS $76.38
- Average True Range (ATR)
- KEN 1.01
- TARS 3.12
- MACD
- KEN 0.31
- TARS 0.08
- Stochastic Oscillator
- KEN 84.43
- TARS 79.27
About KEN Kenon Holdings Ltd.
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include OPC Power Plants, CPV Group, and ZIM. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.